Clinical outcomes of patients with chronic hepatitis C after generic direct-acting antiviral treatments in Vietnam: A retrospective analysis

• 作者: Azumi Ishizaki Hiroshi Ichimura Hoi T Le Huong TT Vu Huyen N Nguyen Kinh V Nguyen Quynh T Nguyen
• 来源期刊: 亚太热带医药杂志（英文版）
• 年，卷（期）: 2020,（11）
• 页码范围: 487-493
• 页数: 7页
• 语种: 英文
• DOI: 10.4103/1995-7645.295358

摘要

Objective: To evaluate the outcomes of generic direct-acting antiviral treatments for chronic hepatitis C in Vietnam.Methods: The medical records of 522 patients (median 45 years; Female, 25.3％) with chronic hepatitis C treated at a tertiary hospital in northern Vietnam in 2016 were retrospectively reviewed. Results: Female patients were significantly older than male patients (median 52, IQR 41-59 vs. 43 years, IQR: 39-55; P<0.001). Among 522 patients, 49.4％ were infected with hepatitis C virus (HCV) genotype 6, followed by 1a (19.0％), 1b (13.0％), and 3 (5.9％). Co-infection with hepatitis B virus or human immunodeficiency virus was noted in 5.8％ and 3.1％ of patients, respectively. Patients were treated with ledipasvir/sofosbuvir with or without ribavirin (70.9％), sofosbuvir/pegylated-interferon + ribavirin (13.2％), daclatasvir/sofosbuvir ?with or without ?ribavirin (12.5％), or sofosbuvir/ribavirin (3.4％), and 96.4％ (n=503) completed the direct-acting antiviral treatment. No patient discontinued treatment due to adverse event(s). A sustained virologic response 12 weeks after the end of the treatment (SVR12) was evaluated in 62.6％ of patients. Overall sustained virologic response 12 weeks after the end of the treatment was 98.7％ regardless of HCV genotypes or direct-acting antiviral regimens. The severity of liver stiffness was significantly decreased from 10.2 to 6.3 kilopascals measured by transient elastography by the treatment (P<0.001). Among patients who completed the direct-acting antiviral treatment, 17.7％ returned for further follow-ups after SVR12. Conclusions: In Vietnam, the current generic direct-acting antiviral treatment for chronic hepatitis C was effective regardless of HCV genotypes and direct-acting antiviral regimens with the attenuation of liver stiffness. It is feasible to implement direct-acting antiviral treatment to cure chronic hepatitis C patients at any liver fibrosis stages in Vietnam.